{"title":"了解药物开发中的权衡:新冠肺炎大流行早期的经验教训回顾","authors":"Debdatta Saha, T. M. Vasuprada","doi":"10.1177/0169796X21996833","DOIUrl":null,"url":null,"abstract":"Using COVID-19 as the backdrop, this article investigates different trade-offs in terms of pecuniary and time costs in drug development across different branches of medicine. South Asian countries as well as China have a rich history of practicing traditional and alternative medicine. However, modern biomedicine as well as traditional medicine comes with certain procedural requirements, which make immediate responses to a pandemic difficult. Clinical trials in biomedicine are costly, mostly in terms of time. On the other hand, a lack of these standards, as in the case of many alternative medicines, does not come with the promise of low-cost cures for the viral pandemic. Any modification of the standards in pharmaceutical testing has resulted in avoidable controversies at all stages of drug discovery, be it in research papers, or in clinical trials, or in the sale of actual medicine itself. Non-pharmaceutical intervention, with different economic impacts, becomes imperative.","PeriodicalId":45003,"journal":{"name":"Journal of Developing Societies","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2021-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/0169796X21996833","citationCount":"2","resultStr":"{\"title\":\"Understanding the Trade-offs in Drug Development: Retrospective on Lessons from the Early Phase of the COVID-19 Pandemic\",\"authors\":\"Debdatta Saha, T. M. Vasuprada\",\"doi\":\"10.1177/0169796X21996833\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Using COVID-19 as the backdrop, this article investigates different trade-offs in terms of pecuniary and time costs in drug development across different branches of medicine. South Asian countries as well as China have a rich history of practicing traditional and alternative medicine. However, modern biomedicine as well as traditional medicine comes with certain procedural requirements, which make immediate responses to a pandemic difficult. Clinical trials in biomedicine are costly, mostly in terms of time. On the other hand, a lack of these standards, as in the case of many alternative medicines, does not come with the promise of low-cost cures for the viral pandemic. Any modification of the standards in pharmaceutical testing has resulted in avoidable controversies at all stages of drug discovery, be it in research papers, or in clinical trials, or in the sale of actual medicine itself. Non-pharmaceutical intervention, with different economic impacts, becomes imperative.\",\"PeriodicalId\":45003,\"journal\":{\"name\":\"Journal of Developing Societies\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2021-04-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1177/0169796X21996833\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Developing Societies\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/0169796X21996833\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"DEVELOPMENT STUDIES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Developing Societies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/0169796X21996833","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DEVELOPMENT STUDIES","Score":null,"Total":0}
Understanding the Trade-offs in Drug Development: Retrospective on Lessons from the Early Phase of the COVID-19 Pandemic
Using COVID-19 as the backdrop, this article investigates different trade-offs in terms of pecuniary and time costs in drug development across different branches of medicine. South Asian countries as well as China have a rich history of practicing traditional and alternative medicine. However, modern biomedicine as well as traditional medicine comes with certain procedural requirements, which make immediate responses to a pandemic difficult. Clinical trials in biomedicine are costly, mostly in terms of time. On the other hand, a lack of these standards, as in the case of many alternative medicines, does not come with the promise of low-cost cures for the viral pandemic. Any modification of the standards in pharmaceutical testing has resulted in avoidable controversies at all stages of drug discovery, be it in research papers, or in clinical trials, or in the sale of actual medicine itself. Non-pharmaceutical intervention, with different economic impacts, becomes imperative.
期刊介绍:
The Journal of Developing Societies is a refereed international journal on development and social change in all societies. JDS provides an interdisciplinary forum for the publication of theoretical perspectives, research findings, case studies, policy analyses and normative critiques on the issues, problems and policies associated with both mainstream and alternative approaches to development. The scope of the journal is not limited to articles on the Third World or the Global South, rather it encompasses articles on development and change in the "developed" as well as "developing" societies of the world. The journal seeks to represent the full range of diverse theoretical and ideological viewpoints on development that exist in the contemporary international community.